Blood Brain Barrier Disruption Chemotherapy
About Craneware Insights
Craneware Insights Articles communicate important regulatory changes to Medicare Outpatient billing, Chargemaster (CDM) and coding compliance. Craneware analyzes Transmittals and bulletins from the Centers for Medicare and Medicaid Services (CMS) and other organizations such as Recovery Audit Contractors (RACs) and emails Insights Articles in a focused manner to alert customers to pertinent regulatory changes.
Regulatory News Topic
Medicare National Coverage Determinations Manual Transmittal 67 (CR 5530), released April 6, 2007, announces that Blood Brain Barrier Disruption Chemotherapy does not meet the reasonable and necessary criteria for the general Medicare population and, therefore, is not a covered service for Medicare beneficiaries.
Date of Insight Article
Tuesday, September 04, 2007
What you need to know and action needed
To view this complete Insights Article including detailed breakdown of Provider Types Affected, Departments Affected, What You Need to Know, Action Needed and Background and Reference links, customers may sign onto Craneware Online Reference Toolkit?.